Clinical Trials Logo
  1. Home
  2. Cushing's Disease
  3. NCT00881283

Long-term Cardiovascular Risk in Cured Cushing's Patients

Cushing's Disease Clinical Trial

Official title:
Role of Adipokines in Long-term Cardiovascular Risk in Cured Cushing's Patients

Clinical Trial Summary

The purpose of this study is to determine whether subjects who have been affected by Cushing's disease in the past maintain some different characteristics compared with subjects who have never been diagnosed with the disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00881283
Study type Observational
Source Massachusetts General Hospital
Contact
Status Terminated
Phase
Start date September 8, 2008
Completion date March 30, 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT02568982 - Cushing's Disease Complications
Completed NCT02697734 - Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Phase 3
Completed NCT01374906 - Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Phase 3
Recruiting NCT03364803 - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Not yet recruiting NCT02603653 - Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease N/A
Completed NCT01371565 - Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Phase 3
Recruiting NCT00845351 - Preoperative Bexarotene Treatment for Cushing's Disease Phase 1/Phase 2
Completed NCT00889525 - Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Phase 3
Completed NCT02060383 - Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Phase 4
Recruiting NCT03474601 - Seoul National University Pituitary Disease Cohort Study
Recruiting NCT04339751 - Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Phase 2
Not yet recruiting NCT04569591 - Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease N/A
Recruiting NCT02484755 - Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Phase 2
Completed NCT01794793 - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Phase 4
Completed NCT00434148 - Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Phase 3
Completed NCT03346954 - Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease N/A
Withdrawn NCT01925092 - Mifepristone in Children With Refractory Cushing's Disease Phase 3
Completed NCT01582061 - An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Phase 3
Recruiting NCT03708900 - Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease Phase 2
Terminated NCT00612066 - Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Phase 2